Sophie Gao

Jan 27, 2025 | thecrimson.com | Sophie Gao |Alexandra Kluzak

Robinson Hall houses Harvard's History department. Harvard professor Vincent A. Brown resigned from a committee within the Harvard & the Legacy of Slavery initiative on Monday, condemning the University's decision to lay off the staff of the Harvard Slavery Remembrance Program. By Michael GritzbachBy Sophie Gao and Alexandra M. Kluzak, Crimson Staff WritersHarvard professor Vincent A.

Jan 27, 2025 | thecrimson.com | Sophie Gao |Alexandra Kluzak

Wadsworth House, the second oldest building at Harvard, is located at 1341 Massachusetts Avenue. By Julian J. GiordanoBy Sophie Gao and Alexandra M. Kluzak, Crimson Staff WritersThe Harvard & the Legacy of Slavery initiative identified at least 913 individuals enslaved by Harvard faculty, staff, and leadership and at least 403 of their living descendants, according to an internal report from December.

Jan 17, 2025 | thecrimson.com | Sophie Gao |Alexandra Kluzak

Hutchins Center Honors hosted the W.E.B. Du Bois Medal Ceremony Wednesday night. Rapper and actor LL Cool J and filmmaker Ava DuVernay were among the honorees. By Allison G. LeeBy Sophie Gao and Alexandra M. Kluzak, Crimson Staff WritersAuthor and journalist Charles M. Blow will leave The New York Times and receive the inaugural Langston Hughes fellowship at Harvard, hosted by the W. E. B. Du Bois Research Institute at the Hutchins Center for African and African American Research.

Jan 17, 2025 | thecrimson.com | Sophie Gao |Alexandra Kluzak

Researchers met with the Antiguan prime minister and governor general to discuss finding descendants. Harvard Slavery Remembrance Program researchers met with top Antiguan officials on Wednesday after identifying hundreds of people who were enslaved by Harvard affiliates in Antigua and Barbuda. By Julian J. GiordanoBy Sophie Gao and Alexandra M. Kluzak, Crimson Staff WritersMembers of the Harvard & the Legacy of Slavery initiative met with Prime Minister Gaston A.

Nov 20, 2024 | rheumatologyadvisor.com | Sophie Gao |Kate A. Shanaghan

Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs. On March 5, 2024, the FDA approved Jubbonti, the first interchangeable biosimilar for Prolia® (denosumab).